moderate-to-severe ulcerative colitis
Rheumatology · 2020–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ustekinumab Severe chronic plaque psoriasis (adult and paediatric), severe psoriatic arthritis, severe Crohn disease, moderate to severe ulcerative colitis, and complex… | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| tofacitinib Review of interchangeability advice for tofacitinib in moderate-to-severe ulcerative colitis (MSUC), severe psoriatic arthritis (PsA), severe active rheumatoid… | Mar 2020 | Deferred | input received Colitis Australia |
Who spoke
Colitis Australia
What the PBS pays
$596M in government benefit over 2024–25, across 122,588 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ustekinumab | $538.3M |
| tofacitinib | $57.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.